复宏汉霖：地舒单抗注射液在欧盟获批上市 覆盖原研所有适应症

Core Viewpoint - Shanghai Fuhong Hanlin Biotechnology Co., Ltd. has received marketing authorization from the European Commission for its biosimilar drug, Duzallo, in two specifications, which covers all indications approved for the original product in the EU [2] Group 1 - The approved specifications for Duzallo are 60mg/mL and 120mg/1.7mL [2] - The approval is seen as a significant achievement for the company and its partners in meeting the needs of European patients and healthcare systems [2] - The company emphasizes its commitment to scientific excellence and product quality, building on its previous approval in the United States [2]